RCC patients are insensitive to radiation, so radical nephrectomy or multitarget tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors are the major treatment modalities for localized and metastatic RCC patients. The gene discussed is MTOR; the disease is renal cell carcinoma.